HC Wainwright Issues Pessimistic Estimate for ARTV Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings estimate for Artiva Biotherapeutics to ($0.90) per share, down from a previous estimate of ($0.74), while maintaining a "Buy" rating with a $12.00 target price.
• The company's last reported earnings were ($0.87) per share, which missed the consensus estimate of ($0.84) by ($0.03).
• In addition to HC Wainwright, Needham & Company has also reduced their price target from $23.00 to $18.00, indicating a cautious outlook on the stock.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a research note issued on Thursday, August 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.90) per share for the quarter, down from their prior forecast of ($0.74). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.55) EPS, FY2026 earnings at ($4.16) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($1.04) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.03).

Separately, Needham & Company LLC reduced their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics has an average rating of "Buy" and an average target price of $17.80.

Artiva Biotherapeutics Trading Up 4.5%

Shares of NASDAQ ARTV opened at $2.76 on Monday. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $17.31. The stock has a fifty day moving average of $2.19 and a 200-day moving average of $2.96.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN boosted its stake in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock valued at $87,000 after buying an additional 3,361 shares during the period. Northern Trust Corp lifted its stake in Artiva Biotherapeutics by 3.8% during the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company's stock worth $1,180,000 after purchasing an additional 4,335 shares during the last quarter. Barclays PLC lifted its stake in Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company's stock worth $244,000 after purchasing an additional 4,545 shares during the last quarter. Geode Capital Management LLC lifted its stake in Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock worth $100,000 after purchasing an additional 7,151 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.